Dr Helen Darling has a PhD in Public Health, she founded global technology company, Oritain in 2007, before co-founding InstatData, a technology company for social listening. 

Helen has held Directorships with a number of organizations, including  the New Zealand Crown Research Institute, Environmental Science Research (ESR) and Export NZ. 

Helen brings to Viropin Pharmaceutical a wealth of international experience in developing high value export businesses and is a past expert on the United States Pharmacopeia committee (Food Integrity). 

Danny Chan is an Investor (Alpha Asset Management) and Director, he is third generation New Zealand Chinese, brought up in Wellington where he received a BCA with honours from Victoria University.

After success overseas in funds management, he developed his own businesses in New Zealand and founded the Academic Colleges Group Limited - the largest private school group in New Zealand.

Danny holds multiple directorships in New Zealand, including both private and public companies.

Dr Anna Campbell has a PhD in biotechnology, extensive commercial science and business experience and a career-long interest in bioactives and human health.

As former Managing Director of AbacusBio, she spearheaded international supply chain and genetic advancement initiatives into 20 countries.

In 2020, Anna co-founded Zestt Wellness, showcasing her commitment to health innovation.

Anna’s biotechnology journey showcases her dedication to advancing health solutions, blending scientific acumen with entrepreneurial spirit to shape the industry landscape.

Darcy Schack is a disruptive innovator, drawing on his diverse technical background in engineering and physics, honed in Canada's oil industry before transitioning into the commercial food sector.

In 2016 Darcy was confronted with a diagnosis of sarcoidosis, a journey that led him to prioritize wellness and ultimately achieve remission.
In 2020, Darcy co-founded Zestt Wellness, driven by his personal journey and a deep commitment to finding health solutions which make a difference in people’s lives.

Darcy’s diverse expertise, coupled with a relentless entrepreneurial spirit, positions him as a disruptive leader in human health.

Andrew is a young entrepreneur that comes from a farming background in the UK and worked on export development for one of the world’s largest fresh produce companies. This experience took him to the Middle Eastern, Asian, and North American markets where Andrew gained his experience in retail and distribution.

Andrew moved to Dubai in 2019 to set up TACCT Global and is also the co-founder of SCARAB Group, a U.A.E.-based investment business specializing in the food sector.

Lisa Shi is experienced in international trade, with extensive knowledge and expertise on China market regulations and access. She immigrated from China to New Zealand 21 years ago and received a Master of Art degree from the University of Auckland.

Lisa teaches at the University of Auckland. She is also a director of export businesses and a partner in biotechnology and medical devices investments.

Greg Cook is a world-leading microbiologist - specializing in bacterial physiology and antimicrobial resistance

Greg is a global expert in tuberculosis disease and bacterial energetics as a new target space for drug development

He also targets antimicrobial resistance and finding new drugs for environmental microorganisms.

Greg received the University of Otago Distinguished Research Medal in 2014 and became a Fellow Royal Society New Zealand in 2013.

Dr Paul Spence is experienced in commercializing scientific innovation at multiple levels from big pharma to VC-backed startup companies.

Paul has a DPhil in Molecular Virology from the University of Oxford. He has conceived, designed and executed the production of a dual HIV antigen diagnostic kit and played a leading role in initiating and managing multi-million-dollar collaborations to develop new drug targets for CNS disorders.

Paul was one of the original inventors of NAMZARIC®, a combination drug product for the treatment of Alzheimer’s disease where he oversaw the Phase 1 development of this product – the drug combination was approved in 2014 and out-licensed.

Paul also contributed to the studies leading to the approval of GOCOVRI® for the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease.